Press release | 16th February 2012

UCB Selects IDBS for Enterprise Research Data Management Platform

E-WorkBook Suite to Provide Informatics and Process Improvements Across Multiple Disciplines to Improve Collaboration and Increase Innovation

Guildford, UK, and Burlington, Mass., February 16, 2012 – IDBS, a global provider of innovative data management, analytics and modeling solutions, today announced that UCB, a global biopharmaceutical company, has selected IDBS to deliver a data management and process development platform across its global research organization.

UCB will deploy E-WorkBook Suite and BioBook across several research divisions to streamline data capture, eliminate data silos, facilitate collaboration and information sharing, reduce complexity and speed time to research.

Senior Director of UCB’s R&D Informatics, Hector Sanchez said: “We were looking for a complete solution combining a feature-rich, flexible product that could be deployed once and provide benefits cross-departmentally combined with unparalleled domain expertise. IDBS was the right choice”.

IDBS founder and CEO, Neil Kipling said: “Our selection by UCB is indicative of the market movement toward enterprise R&D data management solutions. The power of data in an organization cannot be overlooked, and more companies understand that breaking down data silos is the first step to improved efficiencies. We are very happy to provide UCB with a solution that will span multiple divisions within the organization to unlock the value of data and pave the way for collaboration and innovation.”

E-WorkBook Suite is a flexible, extensible framework for the capture, analysis, searching and reporting of experimental data in a compliant, validated environment. It boosts research productivity and efficiency by improving data accessibility, promoting knowledge sharing and reuse of data across an organization, thereby minimizing duplication of work. BioBook brings complete electronic study and data management to late stage discovery and preclinical research.

Media contacts:

Caroline Beer, Account Manager, Metia
T: +44 (0)20 3100 3796 E:

Scott Fleming, Head of UK Communications, UCB
T +44 (0)7702 777378 E:

About UCB

UCB, Brussels, Belgium ( is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8,500 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2010. UCB is listed on Euronext Brussels (symbol: UCB).

About IDBS

IDBS is a global provider of innovative enterprise data management, analytics and modeling solutions. The company’s uniquely sophisticated platform technologies are used by more than 200 pharmaceutical companies, major healthcare providers, global leaders in academic study, and high tech companies to increase efficiency, reduce costs and improve the productivity of industrial R&D and clinical research. IDBS is clearly differentiated by its unique combination of award-winning enterprise technologies and domain knowledge in R&D.

IDBS’ solutions help scientists, hospitals and R&D businesses produce the world’s newest therapeutics, diagnostics and personalized treatments, faster, cleaner engines and fuels, breakthroughs in productive agriculture, healthy, safer food products, and high tech materials and consumer products.

Founded in 1989 and privately held, IDBS is headquartered in Guildford, UK with a direct sales and support presence worldwide. IDBS is a Profit Track 100 company and the recipient of multiple awards including the Frost and Sullivan ‘Enabling Technology’ Award in R&D data management for 2010 and Queen’s Award for International Trade 2011. Further information can be found at, or follow us on Twitter @IDBSsoftware.

About IDBSContact us

More news